Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

in the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, RDEA684, RDEA119, RDEA806, RDEA427 and our other compounds, the timing and results of our preclinical, clinical and other studies, the sufficiency of our cash resources and our financial performance. Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs and risks related to the outcome of our business development activities, including collaboration or licensing agreements. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://www.n
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... Refining convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and ... mobile program, surpassing their original 2015 fundraising goal by nearly $100,000, to ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Ticket Down is a reputable source of authentic ... and the United States vs. Honduras at the Toyota Stadium. , The 2015 ... 7th at Toyota Stadium. The tournament, being held on American soil, will kick off in ...
(Date:7/7/2015)... Washington (PRWEB) , ... July ... ... San Francisco-based Hope Consulting announced today that the two firms have merged ... in the social, health and biopharma sectors. The merger combines SwitchPoint’s strategy ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... solutions, today announced the CelestixEdge VE and CelestixFederated VA Series virtual appliances. ... CelestixFederated A Series portfolio of products, which have proven to simplify the on-premises ...
(Date:7/7/2015)... ... ... SC&H Group, a leading audit, tax, and consulting firm, recently hosted its ... company-wide volunteering efforts. , On an annual basis, in coordination with Business Volunteers ... throughout Baltimore and Washington D.C. , This year, SC&H Group’s team in ...
Breaking Medicine News(10 mins):Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:SC&H Group Celebrates 9th Annual Day of Service 2
... YORK, NORWICH, England and ONGAR, Ireland,Sept. 4 Schofield ... the 29th August that it has acquired Health and,Safety ... Monitor was launched at the same time as the ... tracked the developing,legislation since then. It has been relied ...
... Kicks Off September,s Ovarian Cancer Awareness ... ... Ovarian Cancer,Coalition (NOCC) launched its newest educational initiative, Eva,s Divas,with a celebrity ... be the first to pledge to empower and educate,women nationwide about the ...
... Sept. 4 ULURU Inc. (Amex:,ULU) today announced ... Thomas Weisel,Partners Healthcare Conference at 3:15 p.m. Eastern ... Inc.:, ULURU Inc. is an emerging specialty ... of wound management, plastic surgery and,oral care products ...
... NEW YORK, Sept. 4 Come fall, women are always ... size and fit into their favorite,jeans that have become a ... about how women can look celeb-good in their,jeans and how ... all,while helping the United Way., (See video from ...
... countries, lime juice is,thought to ward off HIV/AIDS. In ... backdrop of misinformation and stigma, how can,developing countries fight ... people?, Part of the answer is to enlist ... an international media development nonprofit that has,provided in-depth training ...
... GAINESVILLE, Fla. --- There,s no magic bullet for wiping ... for a method that effectively delays the evolution of ... researcher says. , David Smith, associate director of disease ... will guide scientists and policy makers in extending the ...
Cached Medicine News:Health News:Schofield Publishing Enters the Newsletter Market 2Health News:National Ovarian Cancer Coalition and CSI: Miami Star Eva La Rue Launch Eva's Divas in Hollywood to Educate Women Nationwide About Ovarian Cancer 2Health News:National Ovarian Cancer Coalition and CSI: Miami Star Eva La Rue Launch Eva's Divas in Hollywood to Educate Women Nationwide About Ovarian Cancer 3Health News:More than 1,000 Journalists Enlisted in Fight Against HIV/AIDS 2Health News:Study: Delaying evolution of drug resistance in malaria parasite possible 2Health News:Study: Delaying evolution of drug resistance in malaria parasite possible 3
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: